August 10, 2022
09:19
Pending US inflation figures, European markets opened lower on Wednesday morning.
The main european scholarships opened lower on Wednesday morning, a few hours before the publication of the highly anticipated US inflation figures and after the cold snap caused by the disappointing forecasts of the American semiconductor manufacturer Micron Technology.
In Brussels, the Bel 20
fell by 0.33% around 9:05 a.m., the index of continuously listed stocks rising, for its part, by 0.25%.
With a gain of almost 2%, Colruyt is leading the increases. The distributor is undoubtedly benefiting from the very good results published this morning by its competitor Ahold Delhaize (+5.5%). The market also welcomes the half-year report from Ageas (+0,9%).
On his side, We open (-2.3%) is a red lantern. Ears fell by 1.9%, Umicore by 1.7% and argenx of 1.7%.
Excluding Bel 20, biotech Bone Therapeutics jumped by more than 40% as part of its merger with a French group. Hyloris takes 2.4% and Exmar 2,2%.
Celyad (-4%), Mithra (-3,1%) et Qrf (-1.4%) lag behind.
Briefing actions belges
>Ageas
will pay an interim dividend for the first time. The parent company of AG Insurance made progress in all its segments and markets in the first half and beat analysts’ expectations. Our article.
>AB InBev
:
* Morgan Stanley raised its target price to 54 euros against 52 euros before. The recommendation remains at “neutral”.
*SocGen has reduced its target price to 51 euros against 52 euros before. The recommendation remains to “sell”.
>Argenx
: Barclays raised its target price to 405 euros against 390 euros before. The recommendation remains to be “overweighted”.
>Ahold Delhaize
exceeds analysts’ expectations and raises its forecasts. Ahold Delhaize exceeded analysts’ expectations in the second quarter by inflating its turnover by 6.4% to 21.45 billion euros.
>Ontex
is set to sell its Brazil operations to conglomerate J&F Investimentos, through its Flora unit, Brazilian newspaper Valor Economico reported on Tuesday. According to the newspaper, Flora, J&F’s hygiene and cleaning products unit, submitted the highest bid.
>Bone Therapeutics
merges with a French biotech and becomes Biosenic. The new company, called Biosenic, will have an expanded portfolio and will remain listed on Euronext Brussels. It will be headed by the current CEO of French biotech Medsenic, François Rieger. Our article.
>even
acquired a new apartment building in the municipality of Hamont-Achel, in the province of Limburg. The building comprises 10 apartments which are currently rented out to private tenants. The release.
>Watch out for this Wednesday. USA. Inflation July 2:30 p.m. Walt Disney results.